TSE:ONC - Oncolytics Biotech Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started C$2.58 -0.04 (-1.53 %) (As of 03/22/2019 04:00 PM ET)Previous CloseC$2.58Today's RangeC$2.56 - C$2.6752-Week RangeC$2.26 - C$10.65Volume34,200 shsAverage Volume32,846 shsMarket CapitalizationC$48.61 millionP/E Ratio-2.42Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck School of Medicine of University of Southern California using pelareorep in combination with Keytruda, Velcade, and dexamethasone to treat multiple myeloma; and a clinical collaboration with SOLTI breast cancer research. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada. Receive ONC News and Ratings via Email Sign-up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange TSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolTSE:ONC Previous Symbol CUSIPN/A CIKN/A Webwww.oncolyticsbiotech.com Phone+1-403-6707380Debt Debt-to-Equity RatioN/A Current Ratio5.14 Quick Ratio4.89Price-To-Earnings Trailing P/E Ratio-2.42 Forward P/E Ratio-3.19 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.78 per share Price / Cash Flow3.32 Book ValueC$0.36 per share Price / Book7.25Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares18,840,000Market CapC$48.61 million Next Earnings Date5/10/2019 (Estimated) OptionableNot Optionable Oncolytics Biotech (TSE:ONC) Frequently Asked Questions What is Oncolytics Biotech's stock symbol? Oncolytics Biotech trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC." When is Oncolytics Biotech's next earnings date? Oncolytics Biotech is scheduled to release their next quarterly earnings announcement on Friday, May 10th 2019. View Earnings Estimates for Oncolytics Biotech. What price target have analysts set for ONC? 1 Wall Street analysts have issued twelve-month price targets for Oncolytics Biotech's shares. Their forecasts range from C$10.00 to C$10.00. On average, they expect Oncolytics Biotech's stock price to reach C$10.00 in the next twelve months. This suggests a possible upside of 287.6% from the stock's current price. View Analyst Price Targets for Oncolytics Biotech. What is the consensus analysts' recommendation for Oncolytics Biotech? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oncolytics Biotech. Has Oncolytics Biotech been receiving favorable news coverage? Media headlines about ONC stock have been trending somewhat positive on Saturday, according to InfoTrie. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oncolytics Biotech earned a news sentiment score of 1.9 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. Who are some of Oncolytics Biotech's key competitors? Some companies that are related to Oncolytics Biotech include Rafael (RFL), OncoCyte (OCX), IMV (IMV), Arix Bioscience (ARIX), Fennec Pharmaceuticals (FRX), Oxford Biodynamics (OBD), Verseon (VSN), Matinas BioPharma (MTNB), Matinas Biopharma (MTNB), Circassia Pharmaceuticals (CIR), Equillium (EQ), Cynata Therapeutics (CYP), Mereo BioPharma Group (MPH), Immutep (IMM) and Neuren Pharmaceuticals (NEU). What other stocks do shareholders of Oncolytics Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONCYF), Aptose Biosciences (APTO), ProMetic Life Sciences (PLI), Resverlogix (RVX), Microbot Medical (MBOT), Niko Resources (NKO), Inovio Pharmaceuticals (INO), Birchcliff Energy (BIR), Helius Medical Technologies (HSDT) and Biopharmx (BPMX). Who are Oncolytics Biotech's key executives? Oncolytics Biotech's management team includes the folowing people: Dr. Matthew C. Coffey, Pres, CEO & DirectorMr. Kirk J. Look, Chief Financial OfficerMr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 52)Mr. Michael Moore, VP of Investor Relations & Corp. CommunicationsDr. Rita Laeufle, Chief Medical Officer How do I buy shares of Oncolytics Biotech? Shares of ONC and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab. What is Oncolytics Biotech's stock price today? One share of ONC stock can currently be purchased for approximately C$2.58. How big of a company is Oncolytics Biotech? Oncolytics Biotech has a market capitalization of C$48.61 million. What is Oncolytics Biotech's official website? The official website for Oncolytics Biotech is http://www.oncolyticsbiotech.com. How can I contact Oncolytics Biotech? Oncolytics Biotech's mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The company can be reached via phone at +1-403-6707380. MarketBeat Community Rating for Oncolytics Biotech (TSE ONC)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 141 (Vote Outperform)Underperform Votes: 112 (Vote Underperform)Total Votes: 253MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote "Outperform" if you believe ONC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/23/2019 by MarketBeat.com StaffFeatured Article: Do back-end load funds outperform no-load funds?